.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CE01_Amrinone.Amrinone

Information

Amrinone is a phosphodiesterase III inhibitor with inotropic and vasodilatory effects, formerly used in the management of congestive heart failure. It increases cardiac contractility and induces vasodilation. Due to safety concerns (notably thrombocytopenia), its use has largely been superseded by other agents and it is not commonly used in clinical practice today.

Pharmacokinetics

Pharmacokinetics in adult patients with congestive heart failure after intravenous administration.

References

1. Allen-Webb, EM, et al., & Banner, W (1994). Age-related amrinone pharmacokinetics in a pediatric population. Critical care medicine 22(6) 1016–1024. DOI:10.1097/00003246-199406000-00022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8205809

2. Bailey, JM, et al., & Hug, CC (1991). Pharmacokinetics of amrinone during cardiac surgery. Anesthesiology 75(6) 961–968. DOI:10.1097/00000542-199112000-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1741517

3. Eason, CT, et al., & Bonner, FW (1988). The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. European journal of drug metabolism and pharmacokinetics 13(2) 129–133. DOI:10.1007/BF03191314 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3145204

Revisions

• 06/2025 initial generated model